Association of MDR-TB treatment outcomes and HIV status in Zimbabwe: A retrospective study

Abstract  MDR-TB has created an additional burden in TB control due to limited treatment options and the generally poor treatment outcomes. We investigated association of MDR-TB treatment outcomes and HIV status in Zimbabwe. The study was a retrospective cohort study of case records from National TB...

Full description

Bibliographic Details
Main Authors: L. Gonah, T. M. Maphosa
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:Cogent Medicine
Subjects:
Online Access:http://dx.doi.org/10.1080/2331205X.2020.1783129
_version_ 1811227349402779648
author L. Gonah
T. M. Maphosa
author_facet L. Gonah
T. M. Maphosa
author_sort L. Gonah
collection DOAJ
description Abstract  MDR-TB has created an additional burden in TB control due to limited treatment options and the generally poor treatment outcomes. We investigated association of MDR-TB treatment outcomes and HIV status in Zimbabwe. The study was a retrospective cohort study of case records from National TB Surveillance System of MDR-TB patients (>16 years) who were culture proven at diagnosis and started treatment between January 2013 and December 2016. Cox proportional hazard regression models were used to assess risk factors associated with mortality. Kaplan–Meier curves were used to determine whether survival probabilities differed for HIV-co-infected and HIV-negative MDR-TB patients. 201 case records were considered for study; 174 cases (87%) started MDR-TB treatment; 11% died before treatment initiation, and 2% did not start treatment. Among 174 cases who were analyzed, 92 were HIV-positive and 82 were HIV-negative. Sixty-three (36%) died during follow up. Number of deaths was not significantly different in patients with or without HIV infection (p = 0.17). Age (25–59 years) (hazard ratio 2.58, 95% CI 1.44–6.77, p = <0.0001) and previous TB treatment (hazard ratio 4.52, 95% CI 1.94–14.2, p = 0.001) were independent predictors of death. Fewer deaths occurred in HIV-infected MDR-TB patients on highly active antiretroviral treatment than those who were not given this therapy (p = 0.01). Treatment outcomes for MDR-TB are likely to be negatively affected by untreated HIV, individual factors and health system factors. National TB control programmes need to be tailored at improving these determinants of MDR-TB and HIV diagnosis and treatment, to improve treatment outcomes.
first_indexed 2024-04-12T09:41:05Z
format Article
id doaj.art-7fcc0045d50c473497d2702fe7206d33
institution Directory Open Access Journal
issn 2331-205X
language English
last_indexed 2024-04-12T09:41:05Z
publishDate 2020-01-01
publisher Taylor & Francis Group
record_format Article
series Cogent Medicine
spelling doaj.art-7fcc0045d50c473497d2702fe7206d332022-12-22T03:38:04ZengTaylor & Francis GroupCogent Medicine2331-205X2020-01-017110.1080/2331205X.2020.17831291783129Association of MDR-TB treatment outcomes and HIV status in Zimbabwe: A retrospective studyL. Gonah0T. M. Maphosa1Midlands State UniversityMidlands State UniversityAbstract  MDR-TB has created an additional burden in TB control due to limited treatment options and the generally poor treatment outcomes. We investigated association of MDR-TB treatment outcomes and HIV status in Zimbabwe. The study was a retrospective cohort study of case records from National TB Surveillance System of MDR-TB patients (>16 years) who were culture proven at diagnosis and started treatment between January 2013 and December 2016. Cox proportional hazard regression models were used to assess risk factors associated with mortality. Kaplan–Meier curves were used to determine whether survival probabilities differed for HIV-co-infected and HIV-negative MDR-TB patients. 201 case records were considered for study; 174 cases (87%) started MDR-TB treatment; 11% died before treatment initiation, and 2% did not start treatment. Among 174 cases who were analyzed, 92 were HIV-positive and 82 were HIV-negative. Sixty-three (36%) died during follow up. Number of deaths was not significantly different in patients with or without HIV infection (p = 0.17). Age (25–59 years) (hazard ratio 2.58, 95% CI 1.44–6.77, p = <0.0001) and previous TB treatment (hazard ratio 4.52, 95% CI 1.94–14.2, p = 0.001) were independent predictors of death. Fewer deaths occurred in HIV-infected MDR-TB patients on highly active antiretroviral treatment than those who were not given this therapy (p = 0.01). Treatment outcomes for MDR-TB are likely to be negatively affected by untreated HIV, individual factors and health system factors. National TB control programmes need to be tailored at improving these determinants of MDR-TB and HIV diagnosis and treatment, to improve treatment outcomes.http://dx.doi.org/10.1080/2331205X.2020.1783129mdr-tbtuberculosishivtreatment outcomeszimbabwe
spellingShingle L. Gonah
T. M. Maphosa
Association of MDR-TB treatment outcomes and HIV status in Zimbabwe: A retrospective study
Cogent Medicine
mdr-tb
tuberculosis
hiv
treatment outcomes
zimbabwe
title Association of MDR-TB treatment outcomes and HIV status in Zimbabwe: A retrospective study
title_full Association of MDR-TB treatment outcomes and HIV status in Zimbabwe: A retrospective study
title_fullStr Association of MDR-TB treatment outcomes and HIV status in Zimbabwe: A retrospective study
title_full_unstemmed Association of MDR-TB treatment outcomes and HIV status in Zimbabwe: A retrospective study
title_short Association of MDR-TB treatment outcomes and HIV status in Zimbabwe: A retrospective study
title_sort association of mdr tb treatment outcomes and hiv status in zimbabwe a retrospective study
topic mdr-tb
tuberculosis
hiv
treatment outcomes
zimbabwe
url http://dx.doi.org/10.1080/2331205X.2020.1783129
work_keys_str_mv AT lgonah associationofmdrtbtreatmentoutcomesandhivstatusinzimbabwearetrospectivestudy
AT tmmaphosa associationofmdrtbtreatmentoutcomesandhivstatusinzimbabwearetrospectivestudy